Clinical Trial

Phase 1 Trial of KH617

Name: Phase 1 Trial of KH617 — clinical trial record (NCT05667194)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2022-12-19; most recent amendment 2024-11-26.

Trial Details

NCT Number	NCT05667194
Lead Sponsor	Sichuan Honghe Biotechnology Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	45 participants
Start Date	2022-12-26
Primary Completion	2030-09 (estimated)
Study Completion	2031-08 (estimated)
Updated on ClinicalTrials.gov	2024-11-27